Moderna moves & Immunocore breaks through: a BioCentury podcast

After its latest readout positioned the company to seek FDA authorization of its COVID-19 vaccine, Moderna has begun to look ahead to unblinding the Phase III trial of mRNA-1273 so participants who received a placebo can be given the chance to be vaccinated. On the latest edition of the BioCentury This Week podcast, BioCentury’s editors discuss the risks and benefits of unblinding the COVE study as well as which COVID-19 vaccines will read out next and what the results are likely to reveal about the different modalities in development.

Then the editors turn to Immunocore, with Senior Editor Lauren Martz explaining how the company has become the first to solve one of the biggest challenges in immuno-oncology...